Epizyme Inc (EPZM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Epizyme Inc (EPZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9837
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases (HMTs) and other chromatin modifying proteins (CMPs). Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, non-hodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc (EPZM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Epizyme Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10
Epizyme Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Epizyme Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Epizyme Enters into Partnership with US Oncology Research 12
Epizyme Enters into Agreement with Genentech 13
Strata Oncology Enters into Agreement with EpiZymev 14
Epizyme Enters into Research Agreement with National Cancer Institute 15
Epizyme Enters into Agreement with Foundation Medicine 16
Epizyme Enters into Agreement with Genentech 17
Epizyme Enters into Agreement with Lymphoma Study Association 18
Licensing Agreements 19
Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 19
Equity Offering 21
Epizyme Raises USD86.2 Million in Public Offering of Shares 21
Epizyme Raises USD161 Million in Public Offering of Shares 23
EpiZyme Raises USD1.9 Million in Public Offering of Shares 25
Epizyme Raises USD138 Million in Public Offering of Shares 26
Epizyme Raises USD139 Million in Public Offering of Shares 28
EpiZyme Announces Exercise Of Underwriters Over Allotment Option Of Public Offering Of Shares For US$107.5 Million 30
EpiZyme Completes IPO For US$89 Million 32
Epizyme Inc – Key Competitors 34
Epizyme Inc – Key Employees 35
Epizyme Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Nov 02, 2018: Epizyme reports third quarter 2018 financial results and Tazemetostat progress 37
Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates 39
May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates 41
Mar 13, 2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 01, 2017: Epizyme Reports Third Quarter 2017 Operating Results and Company Updates 45
Aug 04, 2017: Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress 46
May 08, 2017: Epizyme Reports First Quarter 2017 Results and Provides Corporate Update 48
Mar 09, 2017: Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals 49
Corporate Communications 51
Jul 23, 2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer 51
Mar 12, 2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors 52
Aug 15, 2017: Epizyme Announces Leadership Transition for Finance Organization 53
Mar 09, 2017: Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company 54
Feb 07, 2017: Epizyme Elects Kevin Conroy to its Board of Directors 55
Clinical Trials 56
Dec 11, 2017: Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Epizyme Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Epizyme Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Epizyme Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10
Epizyme Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Epizyme Enters into Partnership with US Oncology Research 12
Epizyme Enters into Agreement with Genentech 13
Strata Oncology Enters into Agreement with EpiZymev 14
Epizyme Enters into Research Agreement with National Cancer Institute 15
Epizyme Enters into Agreement with Foundation Medicine 16
Epizyme Enters into Agreement with Genentech 17
Epizyme Enters into Agreement with Lymphoma Study Association 18
Epizyme Amends Licensing Agreement with Celgene for HMT Inhibitor Programs 19
Epizyme Raises USD86.2 Million in Public Offering of Shares 21
Epizyme Raises USD161 Million in Public Offering of Shares 23
EpiZyme Raises USD1.9 Million in Public Offering of Shares 25
Epizyme Raises USD138 Million in Public Offering of Shares 26
Epizyme Raises USD139 Million in Public Offering of Shares 28
EpiZyme Announces Exercise Of Underwriters Over Allotment Option Of Public Offering Of Shares For US$107.5 Million 30
EpiZyme Completes IPO For US$89 Million 32
Epizyme Inc, Key Competitors 34
Epizyme Inc, Key Employees 35
Epizyme Inc, Subsidiaries 36

List of Figures
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Epizyme Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Epizyme Inc (EPZM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Sherwin-Williams Company:企業の戦略・SWOT・財務情報
    The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report Summary The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tomophase Corp:製品パイプライン分析
    Summary Tomophase Corp (Tomophase) is a medical device company that offers light-based imaging and therapy solutions. The company develops and commercializes opto-medical devices. It offers endoscopic tissue imaging system based on its proprietary technology optical coherence tomography. Tomophase's …
  • QinetiQ Group Plc:企業の戦略・SWOT・財務情報
    QinetiQ Group Plc - Strategy, SWOT and Corporate Finance Report Summary QinetiQ Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Dataprep Holdings Bhd (DATAPRP):企業の財務・戦略的SWOT分析
    Dataprep Holdings Bhd (DATAPRP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Securian Financial Group, Inc.:企業の戦略・SWOT・財務情報
    Securian Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Securian Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Acura Pharmaceuticals Inc (ACUR)-製薬・医療分野:企業M&A・提携分析
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • Kurumoch International Airport:企業の戦略・SWOT・財務情報
    Kurumoch International Airport - Strategy, SWOT and Corporate Finance Report Summary Kurumoch International Airport - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Landis+Gyr AG (LAND):電力:M&Aディール及び事業提携情報
    Summary Landis+Gyr AG (Landis+Gyr) is an integrated energy management company that provide end-to-end advanced metering solutions. It delivers comprehensive services including cloud services, managed services, smart grid services, software services, solutions consulting and support services. The com …
  • Mitsubishi Motors Corporation:企業の戦略・SWOT・財務情報
    Mitsubishi Motors Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Motors Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Reliance Infrastructure Ltd.:企業の戦略・SWOT・財務情報
    Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report Summary Reliance Infrastructure Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Crew Energy Inc (CR):企業の財務・戦略的SWOT分析
    Summary Crew Energy Inc (Crew Energy) is an exploration and production company that offers our long-term production and development of crude oil and natural gas resources. The company offers exploration, development, strategic acquisitions, operations, management, and production programs. It operate …
  • Allan Myers Inc:企業の戦略・SWOT・財務分析
    Allan Myers Inc - Strategy, SWOT and Corporate Finance Report Summary Allan Myers Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • VWR Corp:医療機器:M&Aディール及び事業提携情報
    Summary VWR Corp (VWR), a subsidiary of Avantor Performance Materials Inc, is a medical equipment company that distributes laboratory products, and provides services and solutions. The company offers product such chemicals, reagents, consumables, durable products, scientific equipment and instrument …
  • Alamo Group, Inc.:企業の戦略・SWOT・財務分析
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Giant Eagle, Inc.:戦略・SWOT・企業財務分析
    Giant Eagle, Inc. - Strategy, SWOT and Corporate Finance Report Summary Giant Eagle, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Honda Motor Co., Ltd.:企業の戦略・SWOT・財務情報
    Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Cullen Resources Ltd:企業の財務・戦略的SWOT分析
    Summary Cullen Resources Ltd (Cullen) is a mining company that offers mineral exploration solutions. The company carries out the business of acquisition, exploration, and development of copper, iron, gold, and nickel properties. Its projects include West Pilbara Iron Ore project, Wyloo project, West …
  • 84 Lumber Co:戦略・SWOT・企業財務分析
    84 Lumber Co - Strategy, SWOT and Corporate Finance Report Summary 84 Lumber Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Koninklijke Philips NV (PHIA):企業の財務・戦略的SWOT分析
    Koninklijke Philips NV (PHIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報
    Summary AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆